OWP Pharmaceuticals
OWP Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that develops and commercializes novel oral liquid formulations of approved neuroscience drugs via the FDA 505(b)(2) pathway, serving neurology and psychiatry prescribers and their epilepsy, bipolar, and psychiatric patients.
- Company typePrivate
- Founded2014
- HeadquartersNaperville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What OWP Pharmaceuticals does
OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company founded in 2014 and headquartered in Naperville, Illinois. The company develops novel oral liquid formulations of already-approved therapeutics via the FDA's 505(b)(2) regulatory pathway, targeting indications where no liquid formulation currently exists — primarily epilepsy, bipolar disorder, schizophrenia, ADHD, and major depressive disorder. Its core technology is formulation chemistry that converts existing tablet or capsule drugs into oral suspensions, oral solutions, or powders-for-oral-liquid, with first-to-market filings protected by patents and FDA approvals.
The company's commercial portfolio includes SUBVENITE (lamotrigine) oral suspension — the first liquid formulation of lamotrigine in the United States, FDA-approved September 2025 and commercially launched January 2026 — along with SUBVENITE lamotrigine tablets, generic Lamotrigine Starter Kits (Orange/Blue/Green titration packs), and Roweepra IR (levetiracetam). A pipeline of four additional oral liquid candidates (quetiapine fumarate, atomoxetine HCl, duloxetine HCl, and trazodone HCl) is at various IND- and patent-stage milestones. Revenue is generated through prescription pharmaceutical sales to U.S. healthcare providers in neurology and psychiatry, distributed via standard pharmacy and specialty distributor channels and supported by a commercialization partnership with EVERSANA (originally 2022, expanded October 2025) that provides market access, field sales, and patient services.
OWP operates under a distinctive "Pharmaceutical Social Enterprise 2.0" model in which a portion of profits is donated to ROW Global/ROW Foundation, a public charity that has sponsored more than 140,000 patient prescription months of anti-seizure medication in under-resourced areas worldwide. The company employs 11–50 people and is led by founder and President Scott Boyer (formerly of Abbott and Bristol-Myers Squibb), alongside COO Mary Dunham, CFO Steve Bourne, and CCO Sara Gao.
OWP Pharmaceuticals firmographics
Firmographics- Name
- OWP Pharmaceuticals
- Legal name
- OWP Pharmaceuticals, Inc.
- Website
- https://owppharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OWP Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that develops and commercializes novel oral liquid formulations of approved neuroscience drugs via the FDA 505(b)(2) pathway, serving neurology and psychiatry prescribers and their epilepsy, bipolar, and psychiatric patients.
- Ownership category
- akta.pro rank
OWP Pharmaceuticals industry classification
Industry- Product category
- Neuroscience specialty pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Specialty Care Pharmaceuticals (HLAIAAAB), Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where OWP Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Naperville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
OWP Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Pharmaceutical Product Sales: OWP generates revenue through the sale of branded generic pharmaceuticals including SUBVENITE (lamotrigine tablets and oral suspension), Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). Products are sold to healthcare providers and through pharmaceutical distribution channels.
- Humanitarian Donations Model: A portion of profits is donated to ROW Global/ROW Foundation to support humanitarian efforts in under-resourced areas, supporting epilepsy treatment globally. This is a unique Social Enterprise 2.0 model where commercial success funds philanthropy.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Prescription pharmaceutical products sold to healthcare providers and patients |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
OWP Pharmaceuticals product offering
Product offeringCore offering
OWP Pharmaceuticals develops, manufactures, and commercializes novel oral liquid formulations of approved neuroscience therapeutics under the FDA 505(b)(2) pathway, including SUBVENITE (lamotrigine) tablets and oral suspension, Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). The company sells these prescription pharmaceutical products to U.S. healthcare providers and through pharmaceutical distribution channels, while operating a Pharmaceutical Social Enterprise model that directs a portion of profits to ROW Global for humanitarian epilepsy programs.
Product overview
OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company dedicated to developing and commercializing novel oral liquid formulations. The company operates a dual product portfolio: (1) Currently commercialized products including SUBVENITE (lamotrigine) in both tablet starter kits and oral suspension formulations, generic Lamotrigine Starter Kits, and Roweepra IR (levetiracetam); and (2) A pipeline of reformulated approved therapeutics with no currently available liquid formulations including quetiapine fumarate, trazodone hydrochloride, atomoxetine hydrochloride, and duloxetine hydrochloride, being developed via 505(b)(2) applications for neuroscience conditions such as epilepsy, bipolar disorder, schizophrenia, migraine, ADHD, and depression. OWP's business model involves donating profits to ROW Global for humanitarian purposes supporting epilepsy treatment in under-resourced areas worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Subvenite: Brand name for lamotrigine products including tablets and oral suspension, used for epilepsy and bipolar disorder treatment. Subvenite is OWP's branded generic alternative (AB rated) to Lamictal Starter Kits.
- Subvenite Oral Suspension
- Roweepra IR
Products and services
- SUBVENITE (lamotrigine) Oral Suspension First FDA-approved oral liquid formulation of lamotrigine in the U.S., designed for patients with swallowing challenges and those needing tailored dosing for epilepsy and bipolar disorder. Prescribed by U.S. healthcare providers in neurology and psychiatry.
- SUBVENITE (lamotrigine tablets, USP) Starter Kits Branded generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits, offered in Orange, Blue, and Green kits based on FDA-approved 5-week titration schedules for patients initiating lamotrigine therapy for epilepsy or bipolar disorder.
- Lamotrigine Starter Kits Generic alternative (AB rated) to Lamictal (lamotrigine) Starter Kits, offered as part of OWP's branded generic portfolio for epilepsy treatment, supplied in Orange, Blue, and Green kits for FDA-approved titration schedules.
- Roweepra IR (Levetiracetam) Anti-epileptic medication (levetiracetam immediate release) marketed by OWP for the treatment of epilepsy, part of the company's neuroscience medication portfolio.
Quantifiable outcome
- First liquid formulation of lamotrigine approved in the U.S. (FDA September 2025)
- +2 more outcomes
Companies that use OWP Pharmaceuticals
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
OWP Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
OWP Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- EVERSANAcoreIn October 2025, OWP selected EVERSANA to provide commercialization services for the U.S. launch of SUBVENITE (lamotrigine) oral suspension. This partnership aims to improve access for patients who have difficulty swallowing tablets and is part of a broader partnership targeting global epilepsy treatment access. EVERSANA's commercialization services support market entry and patient reach.
- EVERSANAcoreIn January 2022, OWP partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed at treating neuroscience disorders. EVERSANA provides fully integrated commercialization services including market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, all optimized by data and predictive analytics. In October 2025, EVERSANA was selected to support the U.S. launch of SUBVENITE oral suspension.
- ROW Global/ROW FoundationcoreOWP Pharmaceuticals enjoys an innovative relationship with ROW Global through its hybrid Pharmaceutical Social Enterprise business model. Together they form a concerted organization with shared goals and values. OWP uses commercial success for the common good by supporting humanitarian projects rather than solely maximizing profits. A large portion of OWP profits goes to provide resources for those living with neurological disorders in under-resourced areas of the world. ROW Global has sponsored dozens of programs and granted more than 140,000 patient prescription months of anti-seizure medication. Income to the foundation is directly linked to OWP sales revenues.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
OWP Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Jazz Pharmaceuticals: Jazz Pharmaceuticals is an established specialty pharma company with a significant neurology/CNS portfolio (epilepsy treatments including Xywav, Epidiolex). Comparable as a CNS-focused commercial-stage specialty pharma with branded reformulation strategies and global commercial reach — Jazz represents what OWP could aspire to become at scale.
- Lundbeck: Lundbeck is a global specialty pharma fully dedicated to brain diseases (epilepsy, depression, psychiatry). Comparable as a CNS-focused specialty pharma with branded neuroscience products targeting the same prescriber base as OWP, but at much larger global scale.
- UCB: UCB is a global biopharma with a strong neurology portfolio (Vimpat/lacosamide, Keppra/levetiracetam, Briviact). Comparable as a neuroscience-focused company with branded epilepsy products competing in the same prescriber market as OWP's lamotrigine/levetiracetam portfolio.
- Eisai (U.S. neurology operations): Eisai has a significant neurology franchise including epilepsy treatments (Fycompa, Banzel). Comparable as an established neuroscience pharma with branded CNS products in the same therapeutic categories (epilepsy) as OWP's portfolio.
Direct peers
- Supernus Pharmaceuticals: Supernus is a CNS specialty pharma focused on epilepsy and ADHD (Trokendi XR, Oxtellar XR, Qelbree). Highly comparable to OWP given its neuroscience-only focus, branded specialty formulations of established molecules, and similar patient/provider target audience.
- Upsher-Smith Laboratories: Upsher-Smith is a private specialty/generic pharma with strong CNS presence (lamotrigine, levetiracetam, quetiapine). Direct competitor to OWP in the same molecules and therapeutic categories, with similar reformulation/improved-formulation strategy targeting neuroscience prescribers.
- Zydus Pharmaceuticals USA: Zydus is a global generic/specialty pharma with significant U.S. CNS offerings including lamotrigine and levetiracetam. Comparable as a competing manufacturer/distributor of generic lamotrigine and levetiracetam products in the same therapeutic space as OWP's Roweepra and Lamotrigine Starter Kits.
Emerging players
- Aquestive Therapeutics: Aquestive is a specialty pharma focused on novel delivery formats (oral films, sublingual) for CNS conditions. Comparable as a small-cap CNS-focused company using novel formulation approaches (similar to OWP's 505(b)(2) liquid strategy) to differentiate mature molecules.
- Neos Therapeutics: Neos Therapeutics developed extended-release and orally disintegrating ADHD/CNS medications. Comparable as a small specialty pharma using novel/reformulated CNS delivery formats and pursuing similar prescriber channels (psychiatrists, neurologists).
Others
- Camden Group: ROW Foundation/ROW Global Health is OWP's nonprofit sister organization, funding humanitarian epilepsy treatment globally (140,000+ patient prescription months sponsored). While not a commercial peer, it is a unique ecosystem partner embedded in OWP's social enterprise model and a key element of the company's brand positioning.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
OWP Pharmaceuticals social profiles
Digital presenceOWP Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
OWP Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
OWP Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OWP Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OWP Pharmaceuticals
What does OWP Pharmaceuticals do?
OWP Pharmaceuticals develops, manufactures, and commercializes novel oral liquid formulations of approved neuroscience therapeutics under the FDA 505(b)(2) pathway, including SUBVENITE (lamotrigine) tablets and oral suspension, Lamotrigine Starter Kits, and Roweepra IR (levetiracetam). The company sells these prescription pharmaceutical products to U.S. healthcare providers and through pharmaceutical distribution channels, while operating a Pharmaceutical Social Enterprise model that directs a portion of profits to ROW Global for humanitarian epilepsy programs.
Is OWP Pharmaceuticals a public or private company?
OWP Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was OWP Pharmaceuticals founded?
OWP Pharmaceuticals was founded in 2014. It employs 11 to 50 people.
Where is OWP Pharmaceuticals based?
OWP Pharmaceuticals is headquartered in Naperville, United States, in the North America region.
How does OWP Pharmaceuticals make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are humanitarian Donations Model.
Who are OWP Pharmaceuticals's main competitors?
Broad incumbents on record are Jazz Pharmaceuticals, Lundbeck, UCB and Eisai (U.S. neurology operations). Direct peers are Supernus Pharmaceuticals, Upsher-Smith Laboratories and Zydus Pharmaceuticals USA. Emerging players are Aquestive Therapeutics and Neos Therapeutics. Camden Group is listed as an others.
Does OWP Pharmaceuticals have an API?
No public API is recorded for OWP Pharmaceuticals.
What industry is OWP Pharmaceuticals in?
OWP Pharmaceuticals's product category is Neuroscience specialty pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.